#BEGIN_DRUGCARD DB01769

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C3H6NO4S

# Chemical_IUPAC_Name:
[(2R)-2-amino-2-carboxyethane]sulfonyl

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Double Oxidized Cysteine

# HET_ID:
CSW

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C3H6NO4S/c4-2(3(5)6)1-9(7)8/h2H,1,4H2,(H,5,6)/t2-/m0/s1

# InChI_Key:
InChIKey=GEAMCHVNTOUKJC-REOHCLBHSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1769

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
152.149

# Molecular_Weight_Mono:
152.001753375

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1OEU

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.7

# Predicted_LogS:
-0.45

# Predicted_Water_Solubility:
5.46e+01 g/l

# Primary_Accession_No:
DB01769

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936210

# PubChem_Substance_ID:
46505815

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01040

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
N[C@@H](C[S](=O)=O)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:28 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_10_Cellular_Location:
Not Available

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
Not Available

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
BA000043

# Drug_Target_10_GenBank_ID_Protein:
Not Available

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
GK2698

# Drug_Target_10_Gene_Sequence:
>666 bp
TCACGCCAGTTCTTCCAGCGCGGCGACGACTTTCTCCGCCGTGCTTCGGCTTGATTGCGG
GTTTTGCCCAGTGATCAAGTTGCCGTCGCGCACCGAGAAATCGGTCCACTTCTCGCCGCG
GACGAAATTCGCCCCGCGCAGGCGCAAGGTGGACTCCAACAAAAACGGCATATGGACGTC
AAGCCCGACTTCGCGTTCTTCTTCGTCTGTAAACGACGTGATCGTTTTTCCTTTCACAAT
CGGCGTACCGTCTTTGTATGTGGCGTTCACCAGCCCTGACGGACCGTGGCAGACAGCGGC
GATGATCCGGCCGTCTTCGGCAAACTGCTGCAAGACGTATTGGAGCGTTTCATTGTCGGG
AAAATCGAACATCGTCCCGTGTCCACCGGGAAGGAAAATGGCGTCAAACCCGTGTGCATC
GTCCTTGCTTAAACGTGTTGTGTTCTTCAGCGCTGCTTCCGCCTCGGCCCAAGACGGGTC
TTTTTCATTGATGCTGCGCGGGTCAAGCGGCACATCACCGCCTTGAATGCTCGCCACTTT
CACGTCATACCCTTTTTCTTTAAACACCAAATACGGCACGGCAAACTCTTCAAGCCAAAG
CCCGGTTTTATGGTCGTCGGTGATCGTCGTATGGTTCGTCACCACCATGAGCACTCGTTT
CGTCAT

# Drug_Target_10_General_Function:
Not Available

# Drug_Target_10_General_References:
Not Available

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
4340

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
24399

# Drug_Target_10_Name:
Hypothetical conserved protein

# Drug_Target_10_Number_of_Residues:
221

# Drug_Target_10_PDB_ID:
1U9C

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF01965	DJ-1_PfpI

# Drug_Target_10_Protein_Sequence:
>Hypothetical conserved protein
MTKRVLMVVTNHTTITDDHKTGLWLEEFAVPYLVFKEKGYDVKVASIQGGDVPLDPRSIN
EKDPSWAEAEAALKNTTRLSKDDAHGFDAIFLPGGHGTMFDFPDNETLQYVLQQFAEDGR
IIAAVCHGPSGLVNATYKDGTPIVKGKTITSFTDEEEREVGLDVHMPFLLESTLRLRGAN
FVRGEKWTDFSVRDGNLITGQNPQSSRSTAEKVVAALEELA

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Not Available

# Drug_Target_10_SwissProt_ID:
Q5KWF3

# Drug_Target_10_SwissProt_Name:
Q5KWF3_GEOKA

# Drug_Target_10_Synonyms:
Not Available

# Drug_Target_10_Theoretical_pI:
4.77

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Not Available

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
Not Available

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
CRYBB1

# Drug_Target_11_GenBank_ID_Gene:
U35340

# Drug_Target_11_GenBank_ID_Protein:
Not Available

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
CRYBB1

# Drug_Target_11_Gene_Sequence:
>759 bp
ATGTCTCAGGCTGCAAAGGCCTCGGCCTCGGCCACAGTGGCGGTGAACCCAGGGCCTGAC
ACCAAGGGGAAGGGGGCCCCACCTGCAGGAACATCCCCTAGTCCCGGCACTACCCTGGCC
CCAACAACCGTGCCTATTACCAGCGCCAAGGCGGCGGAACTGCCTCCTGGGAACTACAGG
CTGGTGGTCTTCGAACTGGAAAACTTCCAGGGCCGTCGAGCAGAATTCTCGGGGGAGTGC
TCAAATCTGGCAGACCGTGGCTTCGACCGTGTGCGCAGCATCATTGTCTCCGCGGGACCC
TGGGTCGCCTTTGAGCAGTCCAACTTCCGCGGGGAGATGTTCATCCTGGAGAAGGGCGAG
TACCCTCGCTGGAACACATGGTCGAGCAGCTACCGCAGTGATCGGCTCATGTCCTTCCGG
CCCATCAAAATGGATGCCCAGGAGCACAAAATCTCCCTGTTTGAAGGGGCCAACTTCAAG
GGCAACACCATAGAGATCCAGGGGGACGACGCACCCAGTCTCTGGGTCTACGGCTTCAGT
GACCGCGTGGGCAGCGTGAAGGTCTCCAGTGGAACATGGGTTGGCTATCAGTATCCTGGC
TACCGCGGGTACCAGTACCTCCTAGAGCCTGGTGACTTCCGGCACTGGAATGAGTGGGGA
GCCTTCCAGCCACAGATGCAGTCCCTGCGTCGCCTGCGTGACAAGCAGTGGCACCTCGAG
GGGTCCTTCCCTGTCCTGGCCACAGAGCCCCCCAAGTGA

# Drug_Target_11_General_Function:
Not Available

# Drug_Target_11_General_References:
10591208	Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22. Nature. 1999 Dec 2;402(6761):489-95.
12060738	MacCoss MJ, McDonald WH, Saraf A, Sadygov R, Clark JM, Tasto JJ, Gould KL, Wolters D, Washburn M, Weiss A, Clark JI, Yates JR 3rd: Shotgun identification of protein modifications from protein complexes and lens tissue. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7900-5.
14573871	Van Montfort RL, Bateman OA, Lubsen NH, Slingsby C: Crystal structure of truncated human betaB1-crystallin. Protein Sci. 2003 Nov;12(11):2606-12.
8575764	Hulsebos TJ, Gilbert DJ, Delattre O, Smink LJ, Dunham I, Westerveld A, Thomas G, Jenkins NA, Copeland NG: Assignment of the beta B1 crystallin gene (CRYBB1) to human chromosome 22 and mouse chromosome 5. Genomics. 1995 Oct 10;29(3):712-8.
8626774	David LL, Lampi KJ, Lund AL, Smith JB: The sequence of human betaB1-crystallin cDNA allows mass spectrometric detection of betaB1 protein missing portions of its N-terminal extension. J Biol Chem. 1996 Feb 23;271(8):4273-9.

# Drug_Target_11_HGNC_ID:
HGNC:2397

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
4341

# Drug_Target_11_Locus:
22q11.2|22q12.1

# Drug_Target_11_Molecular_Weight:
28024

# Drug_Target_11_Name:
Beta crystallin B1

# Drug_Target_11_Number_of_Residues:
252

# Drug_Target_11_PDB_ID:
1OKI

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF00030	Crystall

# Drug_Target_11_Protein_Sequence:
>Beta crystallin B1
MSQAAKASASATVAVNPGPDTKGKGAPPAGTSPSPGTTLAPTTVPITSAKAAELPPGNYR
LVVFELENFQGRRAEFSGECSNLADRGFDRVRSIIVSAGPWVAFEQSNFRGEMFILEKGE
YPRWNTWSSSYRSDRLMSFRPIKMDAQEHKISLFEGANFKGNTIEIQGDDAPSLWVYGFS
DRVGSVKVSSGTWVGYQYPGYRGYQYLLEPGDFRHWNEWGAFQPQMQSLRRLRDKQWHLE
GSFPVLATEPPK

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
Crystallins are the dominant structural components of the vertebrate eye lens

# Drug_Target_11_SwissProt_ID:
P53674

# Drug_Target_11_SwissProt_Name:
CRBB1_HUMAN

# Drug_Target_11_Synonyms:
Not Available

# Drug_Target_11_Theoretical_pI:
8.88

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Cytoplasmic

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
Not Available

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
AJ001089

# Drug_Target_12_GenBank_ID_Protein:
Not Available

# Drug_Target_12_GeneCard_ID:
Not Available

# Drug_Target_12_Gene_Name:
aglA

# Drug_Target_12_Gene_Sequence:
>1380 bp
ATGCCATCTGTGAAGATCGGTATCATCGGTGCGGGGAGCGCGGTGTTTTCTCTGAGGCTT
GTGAGTGATCTTTGCAAAACGCCGGGACTCTCTGGCAGCACGGTCACCCTCATGGATATC
GACGAAGAAAGACTCGACGCTATTCTGACCATCGCGAAAAAATACGTTGAAGAAGTGGGA
GCGGATCTGAAATTCGAAAAAACCATGAATTTAGATGACGTCATCATCGACGCGGATTTT
GTGATAAACACAGCGATGGTGGGTGGCCATACCTACTTGGAGAAGGTCAGACAGATCGGT
GAGAAATACGGCTACTACAGAGGAATAGACGCTCAGGAGTTTAACATGGTCTCCGACTAC
TACACCTTCTCCAACTACAACCAGCTCAAGTACTTCGTTGACATAGCAAGGAAGATAGAG
AAGCTCTCCCCAAAAGCCTGGTACTTGCAGGCAGCGAACCCCATTTTCGAGGGAACAACC
CTTGTGACAAGAACGGTTCCCATAAAGGCAGTGGGATTCTGCCATGGACACTACGGCGTG
ATGGAGATCGTAGAGAAACTGGGGCTGGAAGAAGAAAAAGTAGATTGGCAGGTCGCAGGA
GTGAACCACGGTATCTGGCTGAATAGGTTCAGATACAACGGGGGGAACGCGTATCCCCTC
CTTGACAAGTGGATCGAGGAAAAATCAAAAGATTGGAAACCAGAGAACCCCTTCAACGAC
CAGCTCTCTCCCGCCGCGATAGACATGTACAGATTCTACGGTGTGATGCCCATCGGTGAC
ACCGTGAGAAACTCTTCGTGGAGGTACCACAGGGATCTTGAAACCAAGAAGAAGTGGTAC
GGTGAACCCTGGGGAGGAGCAGATTCTGAAATAGGCTGGAAATGGTACCAAGACACGCTT
GGAAAGGTCACGGAGATCACAAAGAAGGTGGCAAAGTTCATCAAAGAAAATCCGTCCGTG
AGGCTCTCCGACCTTGGAAGTGTTCTGGGGAAAGACCTCTCAGAAAAGCAGTTTGTGCTC
GAAGTGGAGAAAATTCTCGATCCAGAAAGAAAGAGTGGAGAGCAGCACATCCCATTCATC
GATGCGCTGCTGAACGATAACAAGGCAAGATTCGTGGTGAACATACCAAATAAAGGTATC
ATTCACGGAATAGACGATGACGTGGTTGTTGAAGTCCCAGCCCTTGTGGACAAGAACGGA
ATCCATCCCGAGAAGATCGAACCACCGCTTCCAGATCGCGTGGTCAAGTACTACCTGAGA
CCCAGAATCATGAGGATGGAAATGGCTCTGGAGGCGTTTCTAACGGGTGACATAAGGATC
ATAAAAGAACTTCTCTACAGAGATCCAAGGACAAAGAGCGATGAACAGGTAGAAAGGTGA

# Drug_Target_12_General_Function:
Involved in hydrolase activity, hydrolyzing O-glycosyl compounds

# Drug_Target_12_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.
10972187	Raasch C, Streit W, Schanzer J, Bibel M, Gosslar U, Liebl W: Thermotoga maritima AglA, an extremely thermostable NAD+-, Mn2+-, and thiol-dependent alpha-glucosidase. Extremophiles. 2000 Aug;4(4):189-200.
12062450	Raasch C, Armbrecht M, Streit W, Hocker B, Strater N, Liebl W: Identification of residues important for NAD+ binding by the Thermotoga maritima alpha-glucosidase AglA, a member of glycoside hydrolase family 4. FEBS Lett. 2002 Apr 24;517(1-3):267-71.
12588867	Lodge JA, Maier T, Liebl W, Hoffmann V, Strater N: Crystal structure of Thermotoga maritima alpha-glucosidase AglA defines a new clan of NAD+-dependent glycosidases. J Biol Chem. 2003 May 23;278(21):19151-8. Epub 2003 Feb 14.
9453151	Bibel M, Brettl C, Gosslar U, Kriegshauser G, Liebl W: Isolation and analysis of genes for amylolytic enzymes of the hyperthermophilic bacterium Thermotoga maritima. FEMS Microbiol Lett. 1998 Jan 1;158(1):9-15.

# Drug_Target_12_HGNC_ID:
Not Available

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
4343

# Drug_Target_12_Locus:
Not Available

# Drug_Target_12_Molecular_Weight:
55048

# Drug_Target_12_Name:
Alpha-glucosidase

# Drug_Target_12_Number_of_Residues:
480

# Drug_Target_12_PDB_ID:
1OBB

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF02056	Glyco_hydro_4

# Drug_Target_12_Protein_Sequence:
>Alpha-glucosidase
MPSVKIGIIGAGSAVFSLRLVSDLCKTPGLSGSTVTLMDIDEERLDAILTIAKKYVEEVG
ADLKFEKTMNLDDVIIDADFVINTAMVGGHTYLEKVRQIGEKYGYYRGIDAQEFNMVSDY
YTFSNYNQLKYFVDIARKIEKLSPKAWYLQAANPIFEGTTLVTRTVPIKAVGFCHGHYGV
MEIVEKLGLEEEKVDWQVAGVNHGIWLNRFRYNGGNAYPLLDKWIEEKSKDWKPENPFND
QLSPAAIDMYRFYGVMPIGDTVRNSSWRYHRDLETKKKWYGEPWGGADSEIGWKWYQDTL
GKVTEITKKVAKFIKENPSVRLSDLGSVLGKDLSEKQFVLEVEKILDPERKSGEQHIPFI
DALLNDNKARFVVNIPNKGIIHGIDDDVVVEVPALVDKNGIHPEKIEPPLPDRVVKYYLR
PRIMRMEMALEAFLTGDIRIIKELLYRDPRTKSDEQVEKVIEEILALPENEEMRKHYLKR

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
Alpha-glycosidase with a very broad specificity. Hydrolyzes maltose and other small maltooligosaccharides but is inactive against the polymeric substrate starch. AglA is not specific with respect to the configuration at the C-4 position of its substrates because glycosidic derivatives of D-galactose are also hydrolyzed. Does not cleave beta-glycosidic bonds

# Drug_Target_12_SwissProt_ID:
O33830

# Drug_Target_12_SwissProt_Name:
AGLA_THEMA

# Drug_Target_12_Synonyms:
EC 3.2.1.20
Maltase

# Drug_Target_12_Theoretical_pI:
5.75

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Not Available

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
Not Available

# Drug_Target_13_GenBank_ID_Gene:
X73124

# Drug_Target_13_GenBank_ID_Protein:
Not Available

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
thiM

# Drug_Target_13_Gene_Sequence:
>819 bp
ATGGATGCACAATCAGCAGCAAAATGTCTTACGGCTGTCCGCCGGCATAGCCCACTGGTG
CATAGCATAACCAACAATGTCGTAACGAATTTCACAGCAAACGGCCTGCTCGCGCTCGGC
GCATCGCCCGTTATGGCGTACGCAAAAGAAGAGGTCGCCGATATGGCGAAAATTGCGGGT
GCACTCGTTTTAAATATCGGAACACTGAGCAAGGAGTCAGTCGAAGCGATGATCATCGCG
GGAAAATCAGCTAATGAACATGGCGTTCCCGTCATTCTTGATCCTGTCGGTGCCGGAGCA
ACACCGTTCCGCACTGAATCGGCACGTGACATCATTCGTGAGGTGCGCCTTGCTGCAATC
AGAGGAAATGCGGCGGAAATTGCCCATACCGTCGGCGTGACCGATTGGCTGATCAAAGGT
GTTGATGCGGGTGAAGGTGGAGGCGACATCATCCGGCTGGCTCAGCAGGCGGCACAAAAG
CTAAACACGGTCATTGCGATAACTGGTGAAGTTGATGTCATAGCCGACACGTCACATGTA
TACACCCTTCATAACGGCCACAAGCTGCTGACAAAAGTGACAGGCGCCGGTTGCCTGCTG
ACTTCCGTCGTCGGTGCGTTTTGCGCTGTGGAAGAAAATCCATTGTTTGCTGCTATTGCG
GCCATTTCTTCGTATGGGGTCGCCGCTCAGCTTGCCGCACAGCAGACGGCTGACAAAGGC
CCTGGAAGCTTTCAGATTGAATTGCTGAACAAGCTTTCAACTGTTACTGAACAAGACGTC
CAAGAATGGGCGACTATAGAAAGGGTGACTGTCTCATGA

# Drug_Target_13_General_Function:
Coenzyme transport and metabolism

# Drug_Target_13_General_References:
10891066	Campobasso N, Mathews II, Begley TP, Ealick SE: Crystal structure of 4-methyl-5-beta-hydroxyethylthiazole kinase from Bacillus subtilis at 1.5 A resolution. Biochemistry. 2000 Jul 11;39(27):7868-77.
7934828	Glaser P, Kunst F, Arnaud M, Coudart MP, Gonzales W, Hullo MF, Ionescu M, Lubochinsky B, Marcelino L, Moszer I, et al.: Bacillus subtilis genome project: cloning and sequencing of the 97 kb region from 325 degrees to 333 degrees. Mol Microbiol. 1993 Oct;10(2):371-84.
9139923	Zhang Y, Taylor SV, Chiu HJ, Begley TP: Characterization of the Bacillus subtilis thiC operon involved in thiamine biosynthesis. J Bacteriol. 1997 May;179(9):3030-5.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_13_HGNC_ID:
Not Available

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
3421

# Drug_Target_13_Locus:
Not Available

# Drug_Target_13_Molecular_Weight:
28214

# Drug_Target_13_Name:
Hydroxyethylthiazole kinase

# Drug_Target_13_Number_of_Residues:
272

# Drug_Target_13_PDB_ID:
1C3Q

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF02110	HK

# Drug_Target_13_Protein_Sequence:
>Hydroxyethylthiazole kinase
MDAQSAAKCLTAVRRHSPLVHSITNNVVTNFTANGLLALGASPVMAYAKEEVADMAKIAG
ALVLNIGTLSKESVEAMIIAGKSANEHGVPVILDPVGAGATPFRTESARDIIREVRLAAI
RGNAAEIAHTVGVTDWLIKGVDAGEGGGDIIRLAQQAAQKLNTVIAITGEVDVIADTSHV
YTLHNGHKLLTKVTGAGCLLTSVVGAFCAVEENPLFAAIAAISSYGVAAQLAAQQTADKG
PGSFQIELLNKLSTVTEQDVQEWATIERVTVS

# Drug_Target_13_Reaction:
ATP + 4-methyl-5-(2-hydroxyethyl)thiazole = ADP + 4-methyl-5-(2-phosphonooxyethyl)thiazole

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
ATP + 4-methyl-5-(2-hydroxyethyl)thiazole = ADP + 4-methyl-5-(2-phosphonooxyethyl)thiazole

# Drug_Target_13_SwissProt_ID:
P39593

# Drug_Target_13_SwissProt_Name:
THIM_BACSU

# Drug_Target_13_Synonyms:
4-methyl-5-beta- hydroxyethylthiazole kinase
EC 2.7.1.50
TH kinase
Thz kinase

# Drug_Target_13_Theoretical_pI:
5.58

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Centrosome

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
CDC25B

# Drug_Target_14_GenBank_ID_Gene:
M81934

# Drug_Target_14_GenBank_ID_Protein:
180173

# Drug_Target_14_GeneCard_ID:
CDC25B

# Drug_Target_14_Gene_Name:
CDC25B

# Drug_Target_14_Gene_Sequence:
>1701 bp
ATGGAGGTGCCCCAGCCGGAGCCCGCGCCAGGCTCGGCTCTCAGTCCAGCAGGCGTGTGC
GGTGGCGCCCAGCGTCCGGGCCACCTCCCGGGCCTCCTGCTGGGATCTCATGGCCTCCTG
GGGTCCCCGGTGCGGGCGGCCGCTTCCTCGCCGGTCACCACCCTCACCCAGACCATGCAC
GACCTCGCCGGGCTCGGCAGCCGCAGCCGCCTGACGCACCTATCCCTGTCTCGACGGGCA
TCCGAATCCTCCCTGTCGTCTGAATCCTCCGAATCTTCTGATGCAGGTCTCTGCATGGAT
TCCCCCAGCCCTATGGACCCCCACATGGCGGAGCAGACGTTTGAACAGGCCATCCAGGCA
GCCAGCCGGATCATTCGAAACGAGCAGTTTGCCATCAGACGCTTCCAGTCTATGCCGGTG
AGGCTGCTGGGCCACAGCCCCGTGCTTCGGAACATCACCAACTCCCAGGCGCCCGACGGC
CGGAGGAAGAGCGAGGCGGGCAGTGGAGCTGCCAGCAGCTCTGGGGAAGACAAGGAGAAT
GATGGATTTGTCTTCAAGATGCCATGGAAGCCCACACATCCCAGCTCCACCCATGCTCTG
GCAGAGTGGGCCAGCCGCAGGGAAGCCTTTGCCCAGAGACCCAGCTCGGCCCCCGACCTG
ATGTGTCTCAGTCCTGACCGGAAGATGGAAGTGGAGGAGCTCAGCCCCCTGGCCCTAGGT
CGCTTCTCTCTGACCCCTGCAGAGGGGGATACTGAGGAAGATGATGGATTTGTGGACATC
CTAGAGAGTGACTTAAAGGATGATGATGCAGTTCCCCCAGGCATGGAGAGTCTCATTAGT
GCCCCACTGGTCAAGACCTTGGAAAAGGAAGAGGAAAAGGACCTCGTCATGTACAGCAAG
TGCCAGCGGCTCTTCCGCTCTCCGTCCATGCCCTGCAGCGTGATCCGGCCCATCCTCAAG
AGGCTGGAGCGGCCCCAGGACAGGGACACGCCCGTGCAGAATAAGCGGAGGCGGAGCGTG
ACCCCTCCTGAGGAGCAGCAGGAGGCTGAGGAACCTAAAGCCCGCGTCCTCCGCTCAAAA
TCACTGTGTCACGATGAGATCGAGAACCTCCTGGACAGTGACCACCGAGAGCTGATTGGA
GATTACTCTAAGGCCTTCCTCCTACAGACAGTAGACGGAAAGCACCAAGACCTCAAGTAC
ATCTCACCAGAAACGATGGTGGCCCTATTGACGGGCAAGTTCAGCAACATCGTGGATAAG
TTTGTGATTGTAGACTGCAGATACCCCTATGAATATGAAGGCGGGCACATCAAGACTGCG
GTGAACTTGCCCCTGGAACGCGACGCCGAGAGCTTCCTACTGAAGAGCCCCATCGCGCCC
TGTAGCCTGGACAAGAGAGTCATCCTCATTTTCCACTGTGAATTCTCATCTGAGCGTGGG
CCCCGCATGTGCCGTTTCATCAGGGAACGAGACCGTGCTGTCAACGACTACCCCAGCCTC
TACTACCCTGAGATGTATATCCTGAAAGGCGGCTACAAGGAGTTCTTCCCTCAGCACCCG
AACTTCTGTGAACCCCAGGACTACCGGCCCATGAACCACGAGGCCTTCAAGGATGAGCTA
AAGACCTTCCGCCTCAAGACTCGCAGCTGGGCTGGGGAGCGGAGCCGGCGGGAGCTCTGT
AGCCGGCTGCAGGACCAGTGA

# Drug_Target_14_General_Function:
Involved in protein tyrosine phosphatase activity

# Drug_Target_14_General_References:
10543950	Reynolds RA, Yem AW, Wolfe CL, Deibel MR Jr, Chidester CG, Watenpaugh KD: Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle. J Mol Biol. 1999 Oct 29;293(3):559-68.
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
1662986	Nagata A, Igarashi M, Jinno S, Suto K, Okayama H: An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some cancer cells. New Biol. 1991 Oct;3(10):959-68.
1836978	Galaktionov K, Beach D: Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell. 1991 Dec 20;67(6):1181-94.
9188863	Baldin V, Cans C, Superti-Furga G, Ducommun B: Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control? Oncogene. 1997 May 22;14(20):2485-95.

# Drug_Target_14_HGNC_ID:
HGNC:1726

# Drug_Target_14_HPRD_ID:
00307

# Drug_Target_14_ID:
3105

# Drug_Target_14_Locus:
20p13

# Drug_Target_14_Molecular_Weight:
64988

# Drug_Target_14_Name:
M-phase inducer phosphatase 2

# Drug_Target_14_Number_of_Residues:
580

# Drug_Target_14_PDB_ID:
1CWR

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00581	Rhodanese
PF06617	M-inducer_phosp

# Drug_Target_14_Protein_Sequence:
>M-phase inducer phosphatase 2
MEVPQPEPAPGSALSPAGVCGGAQRPGHLPGLLLGSHGLLGSPVRAAASSPVTTLTQTMH
DLAGLGSETPKSQVGTLLFRSRSRLTHLSLSRRASESSLSSESSESSDAGLCMDSPSPMD
PHMAEQTFEQAIQAASRIIRNEQFAIRRFQSMPVRLLGHSPVLRNITNSQAPDGRRKSEA
GSGAASSSGEDKENDGFVFKMPWKPTHPSSTHALAEWASRREAFAQRPSSAPDLMCLSPD
RKMEVEELSPLALGRFSLTPAEGDTEEDDGFVDILESDLKDDDAVPPGMESLISAPLVKT
LEKEEEKDLVMYSKCQRLFRSPSMPCSVIRPILKRLERPQDRDTPVQNKRRRSVTPPEEQ
QEAEEPKARVLRSKSLCHDEIENLLDSDHRELIGDYSKAFLLQTVDGKHQDLKYISPETM
VALLTGKFSNIVDKFVIVDCRYPYEYEGGHIKTAVNLPLERDAESFLLKSPIAPCSLDKR
VILIFHCEFSSERGPRMCRFIRERDRAVNDYPSLYYPEMYILKGGYKEFFPQHPNFCEPQ
DYRPMNHEAFKDELKTFRLKTRSWAGERSRRELCSRLQDQ

# Drug_Target_14_Reaction:
protein tyrosine phosphate + H2O = protein tyrosine + phosphate

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. Directly dephosphorylates CDC2 and stimulates its kinase activity. The three isoforms seem to have a different level of activity

# Drug_Target_14_SwissProt_ID:
P30305

# Drug_Target_14_SwissProt_Name:
MPIP2_HUMAN

# Drug_Target_14_Synonyms:
Dual specificity phosphatase Cdc25B
EC 3.1.3.48

# Drug_Target_14_Theoretical_pI:
6.36

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Endoplasmic reticulum
cytoplasmic side
endoplasmic reticulum membrane
peripheral membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PTPN1

# Drug_Target_1_GenBank_ID_Gene:
M31724

# Drug_Target_1_GenBank_ID_Protein:
190742

# Drug_Target_1_GeneCard_ID:
PTPN1

# Drug_Target_1_Gene_Name:
PTPN1

# Drug_Target_1_Gene_Sequence:
>1308 bp
ATGGAGATGGAAAAGGAGTTCGAGCAGATCGACAAGTCCGGGAGCTGGGCGGCCATTTAC
CAGGATATCCGACATGAAGCCAGTGACTTCCCATGTAGAGTGGCCAAGCTTCCTAAGAAC
AAAAACCGAAATAGGTACAGAGACGTCAGTCCCTTTGACCATAGTCGGATTAAACTACAT
CAAGAAGATAATGACTATATCAACGCTAGTTTGATAAAAATGGAAGAAGCCCAAAGGAGT
TACATTCTTACCCAGGGCCCTTTGCCTAACACATGCGGTCACTTTTGGGAGATGGTGTGG
GAGCAGAAAAGCAGGGGTGTCGTCATGCTCAACAGAGTGATGGAGAAAGGTTCGTTAAAA
TGCGCACAATACTGGCCACAAAAAGAAGAAAAAGAGATGATCTTTGAAGACACAAATTTG
AAATTAACATTGATCTCTGAAGATATCAAGTCATATTATACAGTGCGACAGCTAGAATTG
GAAAACCTTACAACCCAAGAAACTCGAGAGATCTTACATTTCCACTATACCACATGGCCT
GACTTTGGAGTCCCTGAATCACCAGCCTCATTCTTGAACTTTCTTTTCAAAGTCCGAGAG
TCAGGGTCACTCAGCCCGGAGCACGGGCCCGTTGTGGTGCACTGCAGTGCAGGCATCGGC
AGGTCTGGAACCTTCTGTCTGGCTGATACCTGCCTCCTGCTGATGGACAAGAGGAAAGAC
CCTTCTTCCGTTGATATCAAGAAAGTGCTGTTAGAAATGAGGAAGTTTCGGATGGGGTTG
ATCCAGACAGCCGACCAGCTGCGCTTCTCCTACCTGGCTGTGATCGAAGGTGCCAAATTC
ATCATGGGGGACTCTTCCGTGCAGGATCAGTGGAAGGAGCTTTCCCACGAGGACCTGGAG
CCCCCACCCGAGCATATCCCCCCACCTCCCCGGCCACCCAAACGAATCCTGGAGCCACAC
AATGGGAAATGCAGGGAGTTCTTCCCAAATCACCAGTGGGTGAAGGAAGAGACCCAGGAG
GATAAAGACTGCCCCATCAAGGAAGAAAAAGGAAGCCCCTTAAATGCCGCACCCTACGGC
ATCGAAAGCATGAGTCAAGACACTGAAGTTAGAAGTCGGGTCGTGGGGGGAAGTCTTCGA
GGTGCCCAGGCTGCCTCCCCAGCCAAAGGGGAGCCGTCACTGCCCGAGAAGGACGAGGAC
CATGCACTGAGTTACTGGAAGCCCTTCCTGGTCAACATGTGCGTGGCTACGGTCCTCACG
GCCGGCGCTTACCTCTGCTACAGGTTCCTGTTCAACAGCAACACATAG

# Drug_Target_1_General_Function:
Involved in protein tyrosine phosphatase activity

# Drug_Target_1_General_References:
11579209	Ravichandran LV, Chen H, Li Y, Quon MJ: Phosphorylation of PTP1B at Ser(50) by Akt impairs its ability to dephosphorylate the insulin receptor. Mol Endocrinol. 2001 Oct;15(10):1768-80.
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
12802338	Salmeen A, Andersen JN, Myers MP, Meng TC, Hinks JA, Tonks NK, Barford D: Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature. 2003 Jun 12;423(6941):769-73.
12802339	van Montfort RL, Congreve M, Tisi D, Carr R, Jhoti H: Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B. Nature. 2003 Jun 12;423(6941):773-7.
1739967	Frangioni JV, Beahm PH, Shifrin V, Jost CA, Neel BG: The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell. 1992 Feb 7;68(3):545-60.
2157211	Chernoff J, Schievella AR, Jost CA, Erikson RL, Neel BG: Cloning of a cDNA for a major human protein-tyrosine-phosphatase. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2735-9.
2164224	Brown-Shimer S, Johnson KA, Lawrence JB, Johnson C, Bruskin A, Green NR, Hill DE: Molecular cloning and chromosome mapping of the human gene encoding protein phosphotyrosyl phosphatase 1B. Proc Natl Acad Sci U S A. 1990 Jul;87(13):5148-52.
2546149	Charbonneau H, Tonks NK, Kumar S, Diltz CD, Harrylock M, Cool DE, Krebs EG, Fischer EH, Walsh KA: Human placenta protein-tyrosine-phosphatase: amino acid sequence and relationship to a family of receptor-like proteins. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5252-6.
8128219	Barford D, Flint AJ, Tonks NK: Crystal structure of human protein tyrosine phosphatase 1B. Science. 1994 Mar 11;263(5152):1397-404.
8491187	Flint AJ, Gebbink MF, Franza BR Jr, Hill DE, Tonks NK: Multi-site phosphorylation of the protein tyrosine phosphatase, PTP1B: identification of cell cycle regulated and phorbol ester stimulated sites of phosphorylation. EMBO J. 1993 May;12(5):1937-46.
9391040	Puius YA, Zhao Y, Sullivan M, Lawrence DS, Almo SC, Zhang ZY: Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13420-5.
9553104	Pannifer AD, Flint AJ, Tonks NK, Barford D: Visualization of the cysteinyl-phosphate intermediate of a protein-tyrosine phosphatase by x-ray crystallography. J Biol Chem. 1998 Apr 24;273(17):10454-62.
9922143	Groves MR, Yao ZJ, Roller PP, Burke TR Jr, Barford D: Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. Biochemistry. 1998 Dec 22;37(51):17773-83.

# Drug_Target_1_HGNC_ID:
HGNC:9642

# Drug_Target_1_HPRD_ID:
01477

# Drug_Target_1_ID:
687

# Drug_Target_1_Locus:
20q13.1-q13.2

# Drug_Target_1_Molecular_Weight:
49967

# Drug_Target_1_Name:
Tyrosine-protein phosphatase non-receptor type 1

# Drug_Target_1_Number_of_Residues:
435

# Drug_Target_1_PDB_ID:
1A5Y

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00102	Y_phosphatase

# Drug_Target_1_Protein_Sequence:
>Tyrosine-protein phosphatase non-receptor type 1
MEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLH
QEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLK
CAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWP
DFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKD
PSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLE
PPPEHIPPPPRPPKRILEPHNGKCREFFPNHQWVKEETQEDKDCPIKEEKGSPLNAAPYG
IESMSQDTEVRSRVVGGSLRGAQAASPAKGEPSLPEKDEDHALSYWKPFLVNMCVATVLT
AGAYLCYRFLFNSNT

# Drug_Target_1_Reaction:
protein tyrosine phosphate + H2O = protein tyrosine + phosphate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
May play an important role in CKII- and p60c-src-induced signal transduction cascades

# Drug_Target_1_SwissProt_ID:
P18031

# Drug_Target_1_SwissProt_Name:
PTN1_HUMAN

# Drug_Target_1_Synonyms:
EC 3.1.3.48
PTP-1B
Protein-tyrosine phosphatase 1B

# Drug_Target_1_Theoretical_pI:
6.21

# Drug_Target_1_Transmembrane_Regions:
409-431

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
PREP

# Drug_Target_2_GenBank_ID_Gene:
X74496

# Drug_Target_2_GenBank_ID_Protein:
558596

# Drug_Target_2_GeneCard_ID:
PREP

# Drug_Target_2_Gene_Name:
PREP

# Drug_Target_2_Gene_Sequence:
>2133 bp
ATGCTGTCCTTCCAGTACCCCGACGTGTACCGCGACGAGACCGCCGTACAGGATTATCAT
GGTCATAAAATTTGTGACCCTTACGCCTGGCTTGAAGACCCCGACAGTGAACAGACTAAG
GCCTTTGTGGAGGCCCAGAATAAGATTACTGTGCCATTTCTTGAGCAGTGTCCCATCAGA
GGTTTATACAAAGAGAGAATGACTGAACTATATGATTATCCCAAGTATAGTTGCCACTTC
AAGAAAGGAAAACGGTATTTTTATTTTTACAATACAGGTTTGCAGAACCAGCGAGTATTA
TATGTACAGGATTCCTTAGAGGGGGAGGCCAGAGTGTTCCTGGACCCCAACATACTGTCT
GACGATGGCACAGTGGCACTCCGAGGTTATGCGTTCAGCGAAGATGGTGAATATTTTGCC
TATGGTCTGAGTGCCAGTGGCTCAGACTGGGTGACAATCAAGTTCATGAAAGTTGATGGT
GCCAAAGAGCTTCCAGATGTGCTTGAAAGAGTCAAGTTCAGCTGTATGGCCTGGACCCAT
GATGGGAAGGGAATGTTCTACAACTCATACCCTCAACAGGATGGAAAAAGTGATGGCACA
GAGACATCTACCAATCTCCACCAAAAGCTCTACTACCATGTCTTGGGAACCGATCAGTCA
GAAGATATTTTGTGTGCTGAGTTTCCTGATGAACCTAAATGGATGGGTGGAGCTGAGTTA
TCTGATGATGGCCGCTATGTCTTGTTATCAATAAGGGAAGGATGTGATCCAGTAAACCGA
CTCTGGTACTGTGACCTACAGCAGGAATCCAGTGGCATCGCGGGAATCCTGAAGTGGGTA
AAACTGATTGACAACTTTGAAGGGGAATATGACTACGTGACCAATGAGGGGACGGTGTTC
ACATTCAAGACGAATCGCCAGTCTCCCAACTATCGCGTGATCAACATTGACTTCTGGGAT
CCTGAAGAGTCTAAGTGGAAAGTACTTGTTCCTGAGCATGAGAAAGATGTCTTAGAATGG
ATAGCTTGTGTCAGGTCCAACTTCTTGGTCTTATGCTACCTCCATGACGTCAAGAACATT
CTGCAGCTCCATGACCTGACTACTGGTGCTCTCCTTAAGACCTTCCCGCTCGATGTCGGC
AGCATTGTAGGGTACAGCGGTCAGAAGAAGGACACTGAAATCTTCTATCAGTTTACTTCC
TTTTTATCTCCAGGTATCATTTATCACTGTGATCTTACCAAAGAGGAGCTGGAGCCAAGA
GTTTTCCGAGAGGTGACCGTAAAAGGAATTGATGCTTCTGATTACCAGACAGTCCAGATT
TTCTACCCTAGCAAGGATGGTACGAAGATTCCAATGTTCATTGTGCATAAAAAAGGCATA
AAATTGGATGGCTCTCATCCAGCTTTCTTATATGGCTATGGCGGCTTCAACATATCCATC
ACACCCAACTACAGTGTTTCCAGGCTTATTTTTGTGAGACACATGGGTGGTATCCTGGCA
GTGGCCAACATCAGAGGAGGTGGCGAATATGGAGAGACGTGGCATAAAGGTGGTATCTTG
GCCAACAAACAAAACTGCTTTGATGACTTTCAGTGTGCTGCTGAGTATCTGATCAAGGAA
GGTTACACATCTCCCAAGAGGCTGACTATTAATGGAGGTTCAAATGGAGGCCTCTTAGTG
GCTGCTTGTGCAAATCAGAGACCTGACCTCTTTGGTTGTGTTATTGCCCAAGTTGGAGTA
ATGGACATGCTGAAGTTTCATAAATATACCATCGGCCATGCTTGGACCACTGATTATGGG
TGCTCGGACAGCAAACAACACTTTGAATGGCTTGTCAAATACTCTCCATTGCATAATGTG
AAGTTACCAGAAGCAGATGACATCCAGTACCCGTCCATGCTGCTCCTCACTGCTGACCAT
GATGACCGCGTGGTCCCGCTTCACTCCCTGAAGTTCATTGCCACCCTTCAGTACATCGTG
GGCCGCAGCAGGAAGCAAAGCAACCCCCTGCTTATCCACGTGGACACCAAGGCGGGCCAC
GGGGCGGGGAAGCCCACAGCCAAAGTGATAGAGGAAGTCTCAGACATGTTTGCGTTCATC
GCGCGGTGCCTGAATGTCGACTGGATTCCATAA

# Drug_Target_2_General_Function:
Amino acid transport and metabolism

# Drug_Target_2_General_References:
7959018	Vanhoof G, Goossens F, Hendriks L, De Meester I, Hendriks D, Vriend G, Van Broeckhoven C, Scharpe S: Cloning and sequence analysis of the gene encoding human lymphocyte prolyl endopeptidase. Gene. 1994 Nov 18;149(2):363-6.
8089089	Shirasawa Y, Osawa T, Hirashima A: Molecular cloning and characterization of prolyl endopeptidase from human T cells. J Biochem (Tokyo). 1994 Apr;115(4):724-9.

# Drug_Target_2_HGNC_ID:
HGNC:9358

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3873

# Drug_Target_2_Locus:
6q22

# Drug_Target_2_Molecular_Weight:
80764

# Drug_Target_2_Name:
Prolyl endopeptidase

# Drug_Target_2_Number_of_Residues:
710

# Drug_Target_2_PDB_ID:
1H2W

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00326	Peptidase_S9
PF02897	Peptidase_S9_N

# Drug_Target_2_Protein_Sequence:
>Prolyl endopeptidase
MLSFQYPDVYRDETAVQDYHGHKICDPYAWLEDPDSEQTKAFVEAQNKITVPFLEQCPIR
GLYKERMTELYDYPKYSCHFKKGKRYFYFYNTGLQNQRVLYVQDSLEGEARVFLDPNILS
DDGTVALRGYAFSEDGEYFAYGLSASGSDWVTIKFMKVDGAKELPDVLERVKFSCMAWTH
DGKGMFYNSYPQQDGKSDGTETSTNLHQKLYYHVLGTDQSEDILCAEFPDEPKWMGGAEL
SDDGRYVLLSIREGCDPVNRLWYCDLQQESSGIAGILKWVKLIDNFEGEYDYVTNEGTVF
TFKTNRQSPNYRVINIDFWDPEESKWKVLVPEHEKDVLEWIACVRSNFLVLCYLHDVKNI
LQLHDLTTGALLKTFPLDVGSIVGYSGQKKDTEIFYQFTSFLSPGIIYHCDLTKEELEPR
VFREVTVKGIDASDYQTVQIFYPSKDGTKIPMFIVHKKGIKLDGSHPAFLYGYGGFNISI
TPNYSVSRLIFVRHMGGILAVANIRGGGEYGETWHKGGILANKQNCFDDFQCAAEYLIKE
GYTSPKRLTINGGSNGGLLVAACANQRPDLFGCVIAQVGVMDMLKFHKYTIGHAWTTDYG
CSDSKQHFEWLVKYSPLHNVKLPEADDIQYPSMLLLTADHDDRVVPLHSLKFIATLQYIV
GRSRKQSNPLLIHVDTKAGHGAGKPTAKVIEEVSDMFAFIARCLNVDWIP

# Drug_Target_2_Reaction:
Hydrolysis of ---Pro! and to a lesser extent ---Ala! in oligopeptides

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Cleaves peptide bonds on the C-terminal side of prolyl residues within peptides that are up to approximately 30 amino acids long

# Drug_Target_2_SwissProt_ID:
P48147

# Drug_Target_2_SwissProt_Name:
PPCE_HUMAN

# Drug_Target_2_Synonyms:
EC 3.4.21.26
PE
Post-proline cleaving enzyme

# Drug_Target_2_Theoretical_pI:
5.58

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
S71932

# Drug_Target_3_GenBank_ID_Protein:
560552

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
Not Available

# Drug_Target_3_Gene_Sequence:
>741 bp
ATGAGCAAGTTATCTGTATTCTTTATATTTTTGTTTTGCAGCATTGCTACCGCAGCAGAG
TCTTTGCCAGATTTAAAAATTGAAAAGCTTGATGAAGGCGTTTATGTTCATACTTCGTTT
GAAGAAGTTAACGGGTGGGGCGTTGTTCCTAAACATGGTTTGGTGGTTCTTGTAAATGCT
GAGGCTTACCTAATTGACACTCCATTTACGGCTAAAGATACTGAAAAGTTAGTCACTTGG
TTTGTGGAGCGTGGCTATAAAATAAAAGGCAGCATTTCCTCTCATTTTCATAGCGACAGC
ACGGGCGGAATAGAGTGGCTTAATTCTCGATCTATCCCCACGTATGCATCTGAATTAACA
AATGAACTGCTTAAAAAAGACGGTAAGGTTCAAGCCACAAATTCATTTAGCGGAGTTAAC
TATTGGCTAGTTAAAAATAAAATTGAAGTTTTTTATCCAGGCCCGGGACACACTCCAGAT
AACGTAGTGGTTTGGTTGCCTGAAAGGAAAATATTATTCGGTGGTTGTTTTATTAAACCG
TACGGTTTAGGCAATTTGGGTGACGCAAATATAGAAGCTTGGCCAAAGTCCGCCAAATTA
TTAAAGTCCAAATATGGTAAGGCAAAACTGGTTGTTCCAAGTCACAGTGAAGTTGGAGAC
GCATCACTCTTGAAACTTACATTAGAGCAGGCGGTTAAAGGGTTAAACGAAAGTAAAAAA
CCATCAAAACCAAGCAACTAA

# Drug_Target_3_General_Function:
Involved in zinc ion binding

# Drug_Target_3_General_References:
8141584	Osano E, Arakawa Y, Wacharotayankun R, Ohta M, Horii T, Ito H, Yoshimura F, Kato N: Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother. 1994 Jan;38(1):71-8.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2840

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
27120

# Drug_Target_3_Name:
Beta-lactamase IMP-1

# Drug_Target_3_Number_of_Residues:
246

# Drug_Target_3_PDB_ID:
1JJT

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00753	Lactamase_B

# Drug_Target_3_Protein_Sequence:
>Beta-lactamase IMP-1 precursor
MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFEEVNGWGVVPKHGLVVLVNA
EAYLIDTPFTAKDTEKLVTWFVERGYKIKGSISSHFHSDSTGGIEWLNSRSIPTYASELT
NELLKKDGKVQATNSFSGVNYWLVKNKIEVFYPGPGHTPDNVVVWLPERKILFGGCFIKP
YGLGNLGDANIEAWPKSAKLLKSKYGKAKLVVPSHSEVGDASLLKLTLEQAVKGLNESKK
PSKPSN

# Drug_Target_3_Reaction:
a beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_3_Signals:
1-18

# Drug_Target_3_Specific_Function:
Confers resistance to imipenem and broad-spectrum beta- lactams. Also hydrolyzes carbapenems

# Drug_Target_3_SwissProt_ID:
P52699

# Drug_Target_3_SwissProt_Name:
BLAB_SERMA

# Drug_Target_3_Synonyms:
BLAIMP
Beta-lactamase IMP-1 precursor
Beta-lactamase type II
EC 3.5.2.6
Penicillinase

# Drug_Target_3_Theoretical_pI:
8.94

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
CDK2

# Drug_Target_4_GenBank_ID_Gene:
X61622

# Drug_Target_4_GenBank_ID_Protein:
29849

# Drug_Target_4_GeneCard_ID:
CDK2

# Drug_Target_4_Gene_Name:
CDK2

# Drug_Target_4_Gene_Sequence:
>897 bp
ATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCACGTACGGAGTTGTGTACAAA
GCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGAG
ACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCAT
CCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTT
GAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCT
CTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCT
CATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCC
ATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACC
CATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTCGAAATATTAT
TCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGG
GCCCTGTTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGG
ACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTC
CCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGG
AGCTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCC
CTGGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGTACCCCATCTTCGACTCTGA

# Drug_Target_4_General_Function:
Involved in protein kinase activity

# Drug_Target_4_General_References:
1396589	Gu Y, Rosenblatt J, Morgan DO: Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 1992 Nov;11(11):3995-4005.
1653904	Tsai LH, Harlow E, Meyerson M: Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase. Nature. 1991 Sep 12;353(6340):174-7.
1714386	Elledge SJ, Spottswood MR: A new human p34 protein kinase, CDK2, identified by complementation of a cdc28 mutation in Saccharomyces cerevisiae, is a homolog of Xenopus Eg1. EMBO J. 1991 Sep;10(9):2653-9.
1717994	Ninomiya-Tsuji J, Nomoto S, Yasuda H, Reed SI, Matsumoto K: Cloning of a human cDNA encoding a CDC2-related kinase by complementation of a budding yeast cdc28 mutation. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9006-10.
7630397	Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich NP: Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature. 1995 Jul 27;376(6538):313-20.
8510751	De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH: Crystal structure of cyclin-dependent kinase 2. Nature. 1993 Jun 17;363(6430):595-602.
8601310	Bourne Y, Watson MH, Hickey MJ, Holmes W, Rocque W, Reed SI, Tainer JA: Crystal structure and mutational analysis of the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1. Cell. 1996 Mar 22;84(6):863-74.
8610110	De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2735-40.
8684460	Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP: Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature. 1996 Jul 25;382(6589):325-31.
8756328	Russo AA, Jeffrey PD, Pavletich NP: Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol. 1996 Aug;3(8):696-700.
8917641	Schulze-Gahmen U, De Bondt HL, Kim SH: High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. J Med Chem. 1996 Nov 8;39(23):4540-6.
9334743	Lawrie AM, Noble ME, Tunnah P, Brown NR, Johnson LN, Endicott JA: Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat Struct Biol. 1997 Oct;4(10):796-801.
9677190	Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ, Schultz PG: Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281(5376):533-8.

# Drug_Target_4_HGNC_ID:
HGNC:1771

# Drug_Target_4_HPRD_ID:
00310

# Drug_Target_4_ID:
2240

# Drug_Target_4_Locus:
12q13

# Drug_Target_4_Molecular_Weight:
33930

# Drug_Target_4_Name:
Cell division protein kinase 2

# Drug_Target_4_Number_of_Residues:
298

# Drug_Target_4_PDB_ID:
1V1K

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_4_Protein_Sequence:
>Cell division protein kinase 2
MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNH
PNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHS
HRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYY
STAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSF
PKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL

# Drug_Target_4_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Probably involved in the control of the cell cycle. Interacts with cyclins A, B3, D, or E. Activity of CDK2 is maximal during S phase and G2

# Drug_Target_4_SwissProt_ID:
P24941

# Drug_Target_4_SwissProt_Name:
CDK2_HUMAN

# Drug_Target_4_Synonyms:
EC 2.7.11.22
p33 protein kinase

# Drug_Target_4_Theoretical_pI:
8.99

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Nucleus. Cytoplasm. Note=Associated with mitochondria in some cells, particularly after oxidative st

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
PARK7

# Drug_Target_5_GenBank_ID_Gene:
D61380

# Drug_Target_5_GenBank_ID_Protein:
30038760

# Drug_Target_5_GeneCard_ID:
PARK7

# Drug_Target_5_Gene_Name:
PARK7

# Drug_Target_5_Gene_Sequence:
>570 bp
ATGGCTTCCAAAAGAGCTCTGGTCATCCTGGCTAAAGGAGCAGAGGAAATGGAGACGGTC
ATCCCTGTAGATGTCATGAGGCGAGCTGGGATTAAGGTCACCGTTGCAGGCCTGGCTGGA
AAAGACCCAGTACAGTGTAGCCGTGATGTGGTCATTTGTCCTGATGCCAGCCTTGAAGAT
GCAAAAAAAGAGGGACCATATGATGTGGTGGTTCTACCAGGAGGTAATCTGGGCGCACAG
AATTTATCTGAGTCTGCTGCTGTGAAGGAGATACTGAAGGAGCAGGAAAACCGGAAGGGC
CTGATAGCCGCCATCTGTGCAGGTCCTACTGCTCTGTTGGCTCATGAAATAGGTTTTGGA
AGTAAAGTTACAACACACCCTCTTGCTAAAGACAAAATGATGAATGGAGGTCATTACACC
TACTCTGAGAATCGTGTGGAAAAAGACGGCCTGATTCTTACAAGCCGGGGGCCTGGGACC
AGCTTCGAGTTTGCGCTTGCAATTGTTGAAGCCCTGAATGGCAAGGAGGTGGCGGCTCAA
GTGAAGGCTCCACTTGTTCTTAAAGACTAG

# Drug_Target_5_General_Function:
Involved in protein binding and oxidative stress sensor

# Drug_Target_5_General_References:
11223268	Taira T, Takahashi K, Kitagawa R, Iguchi-Ariga SM, Ariga H: Molecular cloning of human and mouse DJ-1 genes and identification of Sp1-dependent activation of the human DJ-1 promoter. Gene. 2001 Jan 24;263(1-2):285-92.
11477070	Takahashi K, Taira T, Niki T, Seino C, Iguchi-Ariga SM, Ariga H: DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J Biol Chem. 2001 Oct 5;276(40):37556-63. Epub 2001 Jul 26.
12612053	Niki T, Takahashi-Niki K, Taira T, Iguchi-Ariga SM, Ariga H: DJBP: a novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex. Mol Cancer Res. 2003 Feb;1(4):247-61.
9070310	Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H: DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun. 1997 Feb 13;231(2):509-13.

# Drug_Target_5_HGNC_ID:
HGNC:16369

# Drug_Target_5_HPRD_ID:
03961

# Drug_Target_5_ID:
1434

# Drug_Target_5_Locus:
1p36.33-p36.12

# Drug_Target_5_Molecular_Weight:
19891

# Drug_Target_5_Name:
Protein DJ-1

# Drug_Target_5_Number_of_Residues:
189

# Drug_Target_5_PDB_ID:
1PS4

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF01965	DJ-1_PfpI

# Drug_Target_5_Protein_Sequence:
>Protein DJ-1
MASKRALVILAKGAEEMETVIPVDVMRRAGIKVTVAGLAGKDPVQCSRDVVICPDASLED
AKKEGPYDVVVLPGGNLGAQNLSESAAVKEILKEQENRKGLIAAICAGPTALLAHEIGFG
SKVTTHPLAKDKMMNGGHYTYSENRVEKDGLILTSRGPGTSFEFALAIVEALNGKEVAAQ
VKAPLVLKD

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Acts as a positive regulator of androgen receptor- dependent transcription. May function as a redox-sensitive chaperone and as a sensor for oxidative stress. Prevents aggregation of SNCA. Protects neurons against oxidative stress and cell death. Plays a role in fertilization. Has no proteolytic activity. Has cell-growth promoting activity and transforming activity

# Drug_Target_5_SwissProt_ID:
Q99497

# Drug_Target_5_SwissProt_Name:
PARK7_HUMAN

# Drug_Target_5_Synonyms:
Oncogene DJ1
Parkinson disease protein 7

# Drug_Target_5_Theoretical_pI:
6.78

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Not Available

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
Not Available

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
Not Available

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
Not Available

# Drug_Target_6_Gene_Sequence:
Not Available

# Drug_Target_6_General_Function:
Involved in glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) activity

# Drug_Target_6_General_References:
12777799	Antonyuk SV, Eady RR, Strange RW, Hasnain SS: The structure of glyceraldehyde 3-phosphate dehydrogenase from Alcaligenes xylosoxidans at 1.7 A resolution. Acta Crystallogr D Biol Crystallogr. 2003 May;59(Pt 5):835-42. Epub 2003 Apr 25.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
4336

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
35754

# Drug_Target_6_Name:
Glyceraldehyde 3-phosphate dehydrogenase

# Drug_Target_6_Number_of_Residues:
335

# Drug_Target_6_PDB_ID:
1OBF

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00044	Gp_dh_N
PF02800	Gp_dh_C

# Drug_Target_6_Protein_Sequence:
>Glyceraldehyde 3-phosphate dehydrogenase
TIRVAINGYGRIGRNILRAHYEGGKSHDIEIVAINDLGDPKTNAHLTRYDTAHGKFPGTV
SVNGSYMVVNGDKIRVDANRNPAQLPWGALKVDVVLECTGFFTTKEKAGAHIKGGAKKVI
ISAPGGADVDATVVYGVNHGTLKSTDTVISNASCTTNCLAPLVKPLNDKLGLQDGLMTTV
HAYTNNQVLTDVYHEDLRRARSATMSMIPTKTGAAAAVGDVLPELDGKLNGYAIRVPTIN
VSIVDLSFVAKRNTTVEEVNGILKAASEGELKGILDYNTEPLVSVDYNHDPASSTVDASL
TKVSGRLVKVSSWYDNEWGFSNRMLDTTVALMSAA

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Not Available

# Drug_Target_6_SwissProt_ID:
P83696

# Drug_Target_6_SwissProt_Name:
P83696_ALCXX

# Drug_Target_6_Synonyms:
Not Available

# Drug_Target_6_Theoretical_pI:
7.30

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Cytoplasmic

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
Not Available

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
AY007227

# Drug_Target_7_GenBank_ID_Protein:
Not Available

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
def

# Drug_Target_7_Gene_Sequence:
>552 bp
ATGTTAACAATGAAAGACATCATTAGAGATGGTCATCCAACTTTGCGTCAAAAAGCAGCT
GAGTTAGAATTACCATTAACTAAAGAAGAAAAAGAAACATTAATCGCCATGAGAGAGTTT
TTAGTAAATAGTCAAGATGAGGAAATCGCGAAACGATATGGTTTACGTTCAGGCGTTGGT
TTGGCTGCACCTCAAATTAATATTTCTAAACGTATGATTGCTGTTTTAATACCAGATGAT
GGCAGTGGCAAATCTTATGACTATATGCTTGTGAACCCAAAAATTGTAAGTCATAGCGTT
CAAGAAGCTTATTTACCAACTGGTGAAGGTTGCCTTAGTGTCGATGATAATGTTGCTGGT
CTAGTTCACCGTCATAATAGAATTACAATTAAAGCCAAAGACATCGAAGGTAATGATATA
CAATTACGACTAAAAGGATATCCAGCAATTGTTTTCCAACATGAAATTGACCATTTAAAT
GGTGTAATGTTCTATGATCACATTGACAAAAATCACCCATTACAACCACATACAGATGCT
GTAGAAGTTTAA

# Drug_Target_7_General_Function:
Involved in iron ion binding

# Drug_Target_7_General_References:
Not Available

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
4337

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
20559

# Drug_Target_7_Name:
Peptide deformylase

# Drug_Target_7_Number_of_Residues:
183

# Drug_Target_7_PDB_ID:
1LQW

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF01327	Pep_deformylase

# Drug_Target_7_Protein_Sequence:
>Peptide deformylase
MLTMKDIIRDGHPTLRQKAAELELPLTKEEKETLIAMREFLVNSQDEEIAKRYGLRSGVG
LAAPQINISKRMIAVLIPDDGSGKSYDYMLVNPKIVSHSVQEAYLPTGEGCLSVDDNVAG
LVHRHNRITIKAKDIEGNDIQLRLKGYPAIVFQHEIDHLNGVMFYDHIDKNHPLQPHTDA
VEV

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions (By similarity)

# Drug_Target_7_SwissProt_ID:
P68826

# Drug_Target_7_SwissProt_Name:
DEF_STAAU

# Drug_Target_7_Synonyms:
EC 3.5.1.88
PDF
Polypeptide deformylase

# Drug_Target_7_Theoretical_pI:
6.23

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Cytoplasmic

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
Not Available

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
AE008502

# Drug_Target_8_GenBank_ID_Protein:
Not Available

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
def

# Drug_Target_8_Gene_Sequence:
>612 bp
ATGTCTGCAATAGAACGTATTACAAAAGCTGCTCACTTAATTGATATGAACGATATTATC
CGTGAAGGGAATCCTACTCTACGCACGGTTGCTGAGGAAGTCACTTTCCCCCTATCTGAC
CAGGAAATCATCCTAGGCGAAAAGATGATGCAATTCCTTAAACATTCCCAAGATCCTGTC
ATGGCTGAAAAAATGGGACTCCGCGGTGGTGTTGGACTGGCTGCTCCCCAGTTAGATATC
TCAAAACGCATTATCGCTGTTTTGGTACCTAATATTGTTGAAGAAGGCGAAACTCCACAG
GAAGCCTACGATTTGGAAGCCATTATGTACAATCCAAAAATCGTCTCTCACTCTGTTCAA
GATGCTGCTCTTGGCGAAGGAGAAGGTTGCCTGTCTGTTGACCGTAACGTGCCTGGCTAT
GTTGTTCGCCATGCCCGCGTTACTGTTGACTACTTTGACAAAGATGGAGAAAAACACCGT
ATCAAACTCAAAGGCTACAACTCCATTGTTGTTCAGCATGAAATTGACCACATTAACGGT
ATCATGTTTTACGATCGCATCAATGAAAAAGACCCATTTGCAGTTAAAGATGGTTTACTG
ATTCTTGAATAA

# Drug_Target_8_General_Function:
Involved in iron ion binding

# Drug_Target_8_General_References:
11544234	Hoskins J, Alborn WE Jr, Arnold J, Blaszczak LC, Burgett S, DeHoff BS, Estrem ST, Fritz L, Fu DJ, Fuller W, Geringer C, Gilmour R, Glass JS, Khoja H, Kraft AR, Lagace RE, LeBlanc DJ, Lee LN, Lefkowitz EJ, Lu J, Matsushima P, McAhren SM, McHenney M, McLeaster K, Mundy CW, Nicas TI, Norris FH, O'Gara M, Peery RB, Robertson GT, Rockey P, Sun PM, Winkler ME, Yang Y, Young-Bellido M, Zhao G, Zook CA, Baltz RH, Jaskunas SR, Rosteck PR Jr, Skatrud PL, Glass JI: Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol. 2001 Oct;183(19):5709-17.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
4338

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
22692

# Drug_Target_8_Name:
Peptide deformylase

# Drug_Target_8_Number_of_Residues:
203

# Drug_Target_8_PDB_ID:
1LM6

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF01327	Pep_deformylase

# Drug_Target_8_Protein_Sequence:
>Peptide deformylase
MSAIERITKAAHLIDMNDIIREGNPTLRTVAEEVTFPLSDQEIILGEKMMQFLKHSQDPV
MAEKMGLRGGVGLAAPQLDISKRIIAVLVPNIVEEGETPQEAYDLEAIMYNPKIVSHSVQ
DAALGEGEGCLSVDRNVPGYVVRHARVTVDYFDKDGEKHRIKLKGYNSIVVQHEIDHING
IMFYDRINEKDPFAVKDGLLILE

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions (By similarity)

# Drug_Target_8_SwissProt_ID:
Q8DP79

# Drug_Target_8_SwissProt_Name:
DEF_STRR6

# Drug_Target_8_Synonyms:
EC 3.5.1.88
PDF
Polypeptide deformylase

# Drug_Target_8_Theoretical_pI:
4.87

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Cytoplasmic

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
Not Available

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
AF543301

# Drug_Target_9_GenBank_ID_Protein:
Not Available

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
sucP

# Drug_Target_9_Gene_Sequence:
>1515 bp
ATGAAAAACAAGGTGCAGCTCATCACTTACGCCGACCGCCTTGGCGACGGCACCATCAAG
TCGATGACCGACATTCTGCGCACCCGCTTCGACGGCGTGTACGACGGCGTTCACATCCTG
CCGTTCTTCACCCCGTTCGACGGCGCCGACGCAGGCTTCGACCCGATCGACCACACCAAG
GTCGACGAACGTCTCGGCAGCTGGGACGACGTCGCCGAACTCTCCAAGACCCACAACATC
ATGGTCGACGCCATCGTCAACCACATGAGTTGGGAATCCAAGCAGTTCCAGGACGTGCTG
GCCAAGGGCGAGGAGTCCGAATACTATCCGATGTTCCTCACCATGAGCTCCGTGTTCCCG
AACGGCGCCACCGAAGAGGACCTGGCCGGCATCTACCGTCCGCGTCCGGGCCTGCCGTTC
ACCCACTACAAGTTCGCCGGCAAGACCCGCCTCGTGTGGGTCAGCTTCACCCCGCAGCAG
GTGGACATCGACACCGATTCCGACAAGGGTTGGGAATACCTCATGTCGATTTTCGACCAG
ATGGCCGCCTCTCACGTCAGCTACATCCGCCTCGACGCCGTCGGCTATGGCGCCAAGGAA
GCCGGCACCAGCTGCTTCATGACCCCGAAGACCTTCAAGCTGATCTCCCGTCTGCGTGAG
GAAGGCGTCAAGCGCGGTCTGGAAATCCTCATCGAAGTGCACTCCTACTACAAGAAGCAG
GTCGAAATCGCATCCAAGGTGGACCGCGTCTACGACTTCGCCCTGCCTCCGCTGCTGCTG
CACGCGCTGAGCACCGGCCACGTCGAGCCCGTCGCCCACTGGACCGACATACGCCCGAAC
AACGCCGTCACCGTGCTCGATACGCACGACGGCATCGGCGTGATCGACATCGGCTCCGAC
CAGCTCGACCGCTCGCTCAAGGGTCTCGTGCCGGATGAGGACGTGGACAACCTCGTCAAC
ACCATCCACGCCAACACCCACGGCGAATCCCAGGCAGCCACTGGCGCCGCCGCATCCAAT
CTCGACCTCTACCAGGTCAACAGCACCTACTATTCGGCGCTCGGGTGCAACGACCAGCAC
TACATCGCCGCCCGCGCGGTGCAGTTCTTCCTGCCGGGCGTGCCGCAAGTCTACTACGTC
GGCGCGCTCGCCGGCAAGAACGACATGGAGCTGCTGCGTAAGACGAATAACGGCCGCGAC
ATCAATCGCCATTACTACTCCACCGCGGAAATCGACGAGAACCTCAAGCGTCCGGTCGTC
AAGGCCCTGAACGCGCTCGCCAAGTTCCGCAACGAGCTCGACGCGTTCGACGGCACGTTC
TCGTACACCACCGATGACGACACGTCCATCAGCTTCACCTGGCGCGGCGAAACCAGCCAG
GCCACGCTGACGTTCGAGCCGAAGCGCGGTCTCGGTGTGGACAACACTACGCCGGTCGCC
ATGTTGGAATGGGAGGATTCCGCGGGAGACCACCGTTCGGATGATCTGATCGCCAATCCG
CCTGTCGTCGCCTGA

# Drug_Target_9_General_Function:
Involved in catalytic activity

# Drug_Target_9_General_References:
Not Available

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
4339

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
56190

# Drug_Target_9_Name:
Sucrose phosphorylase

# Drug_Target_9_Number_of_Residues:
504

# Drug_Target_9_PDB_ID:
1R7A

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00128	Alpha-amylase

# Drug_Target_9_Protein_Sequence:
>Sucrose phosphorylase
MKNKVQLITYADRLGDGTIKSMTDILRTRFDGVYDGVHILPFFTPFDGADAGFDPIDHTK
VDERLGSWDDVAELSKTHNIMVDAIVNHMSWESKQFQDVLAKGEESEYYPMFLTMSSVFP
NGATEEDLAGIYRPRPGLPFTHYKFAGKTRLVWVSFTPQQVDIDTDSDKGWEYLMSIFDQ
MAASHVSYIRLDAVGYGAKEAGTSCFMTPKTFKLISRLREEGVKRGLEILIEVHSYYKKQ
VEIASKVDRVYDFALPPLLLHALSTGHVEPVAHWTDIRPNNAVTVLDTHDGIGVIDIGSD
QLDRSLKGLVPDEDVDNLVNTIHANTHGESQAATGAAASNLDLYQVNSTYYSALGCNDQH
YIAARAVQFFLPGVPQVYYVGALAGKNDMELLRKTNNGRDINRHYYSTAEIDENLKRPVV
KALNALAKFRNELDAFDGTFSYTTDDDTSISFTWRGETSQATLTFEPKRGLGVDNTTPVA
MLEWEDSAGDHRSDDLIANPPVVA

# Drug_Target_9_Reaction:
Not Available

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Not Available

# Drug_Target_9_SwissProt_ID:
Q84HQ2

# Drug_Target_9_SwissProt_Name:
Q84HQ2_BIFAD

# Drug_Target_9_Synonyms:
EC 2.4.1.7

# Drug_Target_9_Theoretical_pI:
4.77

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB01769
